ReviewFrontiers in endocrinology2024

A novel class of oral, non-immunosuppressive, beta cell-targeting, TXNIP-inhibiting T1D drugs is emerging.

Gu Jing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.